Blar i forfatter "Arnes, Marit"
-
HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
Ørbo, Anne; Arnes, Marit; Lyså, Lena Marianne Myreng; Borgfelt, Christer; Straume, Bjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-08-18)Background: The aim of the present study was to investigate whether changes in the tissue expression of human epididymisspecific protein 4 (HE4) could predict therapy resistance and relapse after progestin hormone therapy for medium- and low-risk endometrial hyperplasia.<p> <p>Methods: Endometrial biopsies were obtained from women participating in a multicentre RCT performed according to the ... -
Intrauterine progestin therapy as a new approach to premalignant endometrial polyps: A prospective observational study
Sletten, Elise Thoresen; Arnes, Marit; Vereide, Anne Beate; Ørbo, Anne (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-09)Background/Aim: Endometrial hyperplastic polyps (EHP) may progress to endometrial carcinoma (EC) if left untreated. We aimed to prospectively investigate the efficacy of the low-dose levonorgestrel intrauterine system (LNG-IUS) as therapy for EHP with malignant potential. Patients and Methods: In total, 37 women with EHP underwent therapy with LNG-IUS containing 13.5 mg levonorgestrel for six months ... -
Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: A national multicentre randomised trial
Ørbo, Anne; Vereide, Anne Beate; Arnes, Marit; Pettersen, Inger; Straume, Bjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2014) -
Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens
Ørbo, Anne; Arnes, Marit; Vereide, Anne Beate; Straume, Bjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-12-02)Objective To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena ) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response.<p> <p>Design A multicentre randomised trial.<p> <p>Setting Ten different ... -
Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study
Sletten, Elise Thoresen; Arnes, Marit; Lyså, Lena Marianne Myreng; Larsen, Marthe; Ørbo, Anne (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-25)<p><i>Objective - </i>After successful progestin therapy for endometrial hyperplasia (EH), the risk of relapse remains. We aimed to assess if immunohistochemical (IHC) expression of progesterone receptor isoforms, PR‐A and PR‐B, in endometrial glands and stroma in pre‐treatment endometrial biopsies was related to relapse of EH. <p><i>Design and setting - </i>Biopsy material originated from women ...